Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Cautions On Zyprexa Use For Dementia-Related Psychosis In Elderly

This article was originally published in The Pink Sheet Daily

Executive Summary

"Dear Doctor" letter calls attention to clinical trial data showing increased incidence of mortality and cerebrovascular events compared to placebo. Lilly has discontinued studying Zyprexa in elderly patients with dementia.

You may also be interested in...



Antipsychotic "Black Box" Warning Will Caution Against Off-Label Use In Dementia

FDA is requesting class labeling describing clinical trial results that show a higher rate of mortality in patients treated with atypical antipsychotics for dementia-related behavioral disorders compared to placebo. FDA's public health advisory and physician alert affect seven products.

Antipsychotic "Black Box" Warning Will Caution Against Off-Label Use In Dementia

FDA is requesting class labeling describing clinical trial results that show a higher rate of mortality in patients treated with atypical antipsychotics for dementia-related behavioral disorders compared to placebo. FDA's public health advisory and physician alert affect seven products.

Abilify Adds Bipolar Maintenance Claim And Cerebrovascular Warning

Bristol-Myers Squibb/Otsuka's atypical antipsychotic becomes second drug in class, after Lilly's Zyprexa, with bipolar maintenance indication. Abilify also joins Zyprexa and J&J's Risperdal with warning on cerebrovascular adverse events in elderly dementia patients.

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel